This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join BNMS | Print Page | Contact Us | Sign In
Industry News
Share |
Industry News

Serac Imaging Systems to develop a compact, hybrid optical/gamma camera which will be portable, smaller, easier to use and more cost effective than anything that exists on the market today

Please find below and attached a press release announcing the formation of a new molecular imaging company, Serac Imaging Systems, which has been established to develop a highly innovative, miniature, hybrid gamma/optical camera (HGC) which will be portable, cheaper, smaller and easier to use than anything that exists on the market today. The IP for the HGC has been exclusively licensed from a group of universities led by the University of Leicester.

SIS Press Release


Theranostics: New hope for late stage prostate cancer patients with an innovative UK-first treatment

Dr Yong Du, Clinical Director Theranostics; Julie Martin, Business Development Theranostics; Emma Spellman Head of Theranostics and Imaging UK and Dan McGowan, Research Physicist – Nuclear Medicine.

The first patients in the UK have now received an innovative theranostics treatment for advanced prostate cancer at GenesisCare, giving new hope for men who have exhausted other treatment options. The UK’s largest private cancer care provider, GenesisCare, announced today that the service is now available at its centre in Windsor for the first time in the UK.

Press Release


Blue Earth press release

Blue Earth Diagnostics continues to expand access to Axumin (fluciclovine (18F)) in Europe

Blue Earth Diagnostics continues to expand


Blue Earth Diagnostics’ latest press release

Announcing the addition of Axumin® (fluciclovine (18F)) to the EAU guidelines for imaging in patients with biochemical recurrence in Prostate Cancer.

The aim of the EAU Guidelines is to assist practicing clinicians in making informed decisions in a given circumstance; taking the highest quality scientific data, their patient’s personal circumstances, values and preferences into account. This is great news for BED as it’s a clear recognition of the clinical value of Axumin in Europe.

Press Release


Blue Earth Diagnostics celebrates 5 year anniversary

Press Release - Blue Earth Diagnostics celebrates five years

Press Release


Blue Earth Diagnostics’ Latest Press Release

Blue Earth Diagnostics’ latest press release announcing the first production and administration of Axumin® (fluciclovine (18F)) in Italy. This news demonstrates our continued commitment to maximize access to Axumin across Europe.

Press Release


Brexit Update From Curium - Updated

Please find the most recent information surrounding our Brexit contingency plans

Feb 2019 Curium Brexit Contigency updated



© 2013 BNMS unless otherwise stated.
The BNMS is a registered as a company in England and Wales with number 08082786.  The BNMS is a charity governed by the rules of the Charity Commission for England and Wales - Registered Number 1150234.  Registered Office: The Royal College of Physicians, 11 St. Andrew's Place, Regent's Park, London NW1 4LE.
The British Nuclear Medicine Society is not able to give specific clinical advice to members of the public. If you are concerned about your scan or therapy please seek the opinion of a nuclear medicine clinician where you were seen or the clinician who referred you to the department or your GP.
Enquiries related to issues such as internships and work experience opportunities, should be directed to the relevant professional body e.g., for radiologists, this will be the Royal College of Radiologists.